Diabetic nephropathy ranks as the most devastating kidney disease worldwide. It characterizes in the early onset by glomerular hypertrophy, hyperfiltration and mesangial expansion. Experimental models show that overproduction of vascular endothelial growth factor (VEGF) is a pathogenic condition for podocytopathy; however the mechanisms that regulate this growth factor induction are not clearly identified. We determined that the adenosine A 2B receptor (A 2B AR) mediates VEGF overproduction in ex vivo glomeruli exposed to high glucose concentration, requiring PKCa and Erk1/2 activation. The glomerular content of A 2B AR was concomitantly increased with VEGF at early stages of renal disease in streptozotocin-induced diabetic rats. Further, in vivo administration of an antagonist of A 2B AR in diabetic rats blocked the glomerular overexpression of VEGF, mesangial cells activation and proteinuria. In addition, we also determined that the accumulation of extracellular adenosine occurs in glomeruli of diabetic rats. Correspondingly, raised urinary adenosine levels were found in diabetic rats. In conclusion, we evidenced that adenosine signaling at the onset of diabetic kidney disease is a pathogenic event that promotes VEGF induction.
Diabetes mellitus is a metabolic disease showing a dramatic increase of affected people worldwide. 1 Diabetic nephropathy (DN) is a diabetes-derived complication that continues to be the primary cause of terminal renal illness throughout the world, 2 affecting up to 30% of diabetic people. Patients with DN live with a high risk of developing cardiovascular disease and their quality of life worsens with progression of the disease. The economic and social impacts of the illness are high, as DN predisposes patients to undergo hemodialysis programs and possible renal transplant at advanced stages. Up to date, strict controls of glycemia and arterial blood pressure, as well as the use of the renin-angiotensin system blockers have been only modestly successful in retarding DN progression. 3, 4 Thus, identification of new therapeutic alternatives remains to be a challenge for research in this field.
It has been shown at the onset of DN that podocytopathy and alterations of the filtration barrier occur, which clinically correspond to hyperfiltration and microalbuminuria. In addition, mesangial expansion with exacerbated extracellular matrix accumulation is a remarkable feature of this disease, which histologically appears as glomeruloesclerosis. 5 The disruption of the vascular endothelial growth factor (VEGF)/ nitric oxide axis has been recognized as a key event leading to the progression of DN. 6 Further, overproduction of VEGF in transgenic animals is sufficient to resemble the glomerular alterations seen in DN. 7, 8 Moreover, biopsies from type 1 and type 2 diabetic patients with early renal damage show an increased glomerular VEGF. [9] [10] [11] [12] [13] Therefore, identification of upstream mediators of VEGF overproduction is critical for identifying the pathogenesis of this disease.
Interestingly, early observations in the diabetic rat kidney showed that adenosine levels were significantly increased in the renal vein plasma compared with the renal artery. 14 It has been described that the equilibrative nucleoside transporters (ENTs), characterized by its sodium-independent facilitative transport activity, could have a major contribution on adenosine availability for signaling through adenosine receptor (AR). [15] [16] [17] [18] [19] [20] [21] ENTs activity mediates adenosine uptake to be either metabolized intracellularly, or to accumulate outside when the uptake activity is reduced. We have previously determined that the ENT1's activity decreased in diabetic rats' glomeruli 22 therefore, the handling of the nucleoside could be altered in this pathologic condition.
The cellular effects of adenosine are mediated by the P 1 purinoceptor family enclosing A 1 , A 2A , A 2B and A 3 AR subtypes. 23 Studies about the role of AR in the progression of DN in rats have attributed to the A 2A subtype, a possible protective role in preventing inflammation-associated renal injury, 24 while a controversial role has been attributed to A 1 subtype in mediating glomerular hyperfiltration. 25, 26 We have determined that the nucleoside adenosine is a regulator of the VEGF production in glomeruli of rat in vitro. 27 Therefore, the correlation of adenosine levels and alterations of glomerular functions in the diabetic state, as well as the possible pharmacological intervention remain to be explored in vivo.
In this study, we show the role of adenosine A 2B receptor (A 2B AR) in mediating glomerular VEGF induction, which could be relevant in the pathological context because it correlates both the activity of a low-affinity receptor and the increased adenosine levels with the establishment of the diabetic glomerulopathy.
MATERIALS AND METHODS

Ex Vivo Glomeruli Assays
Glomeruli were isolated from rat kidney cortex using a differential sieving method. 28 Freshly purified glomeruli (10 000 per well) were incubated in 2 ml of HAM-F10 medium (Invitrogen, Grand Island, NY, USA) supplemented with 1 mmol/l NECA (non-selective P 1 receptors agonist), 50 nmol/l MRS1754 (A 2B AR antagonist), 30 nmol/l CPA (A 1 AR agonist), 30 nmol/l DPCPX (A 1 AR antagonist), all from Tocris Cookson (Ellisville, MO, USA) at standard conditions (37 1C and 5% CO 2 ) for 6 h. Also, supplementation with D-glucose 25 mM was carried out for 24 h. Five millimoles of D-glucose and supplementation with D-mannitol were included as controls. Following incubation, the glomeruli were collected by centrifugation and supernatants were stored at À 70 1C. Total protein extracts were obtained from glomeruli resuspended in 150 ml RIPA buffer containing protease inhibitors 1 mM PMSF, 2 mM aprotinin, 1 mg/ml leupeptin and pepstatin (Roche, Indianapolis, IN, USA).
Short Interfering RNA
The generation of an adenoviral vector that codes a short interfering RNA targeting the sequence 5 0 -AACAGUAAA GACCGUGCCACC-3 0 of rat A 2B AR mRNA (nucleotides 540-560) or the scrambled sequence 5 0 -ACGUGAGA CACCGAACCUAAC-3 0 were constructed using pSilencer adeno 1.0-CMV System (Ambion, Austin, TX, USA). Efficient inhibition of A 2B AR expression was obtained following 48 h from adenoviral infection of glomeruli in HAM-F10 medium (see Supplementary Figure 2 ).
Western Blots
Total proteins extracts (50 mg) fractionated by polyacrylamide gel (10%) electrophoresis were transferred to nitrocellulose membranes and probed with anti-VEGF antibody (1:1000) (ab46154 from Abcam, Cambridge, MA, USA). Membranes were washed in Tris buffer saline 0.1% Tween, and incubated 1 h in TBST/0.1% BSA containing HRP-conjugated goat antirabbit IgG antibody. Immunodetections were revealed by enhanced chemiluminescence and quantitated by densitometry. Following the stripping procedure, the membranes were probed with a monoclonal anti-b actin antibody (1:5000) (Sigma-Aldrich, St Louis, MO, USA) and revealed, as described above.
Enzyme-Linked Immunosorbent Assay
The amounts of VEGF secreted by glomeruli were measured by a quantitative solid-phase Enzyme-Linked Immunosorbent Assay enzyme immunoassay designed to recognize rat VEGF164 (R&D Systems, Minneapolis, MN, USA). The sensitivity of the assay was 8.4 pg/ml.
Adenine Nucleotides and Adenosine Quantifications
Total glomeruli freshly purified from individual rat were incubated in 1 ml of tyrode's buffer at 37 1C and 5% CO 2 for 1 h. Incubation medium and glomeruli were separated by centrifugation at 2000 g for 5 min. The adenine nucleotides and adenosine contents in supernatants were quantified 
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Animals and Treatments
All animal studies were approved by the institutional animal care and use committee at Universidad Austral 
Immunohistochemistry
Rat kidney tissues were fixed in formalin, paraffin embedded and 5 mm sections were mounted on sylanized slides. Immunodetection was performed as described previously 22 using the primary anti-A 2B AR, anti-A 1 AR, anti-VEGF and anti-nephrin polyclonal antibodies (ab40002, ab46154 and ab58968 from Abcam), and the monoclonal anti-a-smooth muscle actin (aSMA) (sc130617 from Santa Cruz Biotechnology, Santa Cruz, CA, USA). The immunosignals were revealed using the LSAB þ System-HRP system (Dako, Carpinteria, CA, USA). The podocytes number was estimated by counting Wilms tumor protein (WT)-1-stained nuclei in 30 glomeruli representatives of each group. Glomerular injury characterized by mesangial expansion was graded on the basis of the extent of glomerular staining using Periodicacid Schiff (PAS) on a scale of 1-3 as follows: 1, normal; 2, mild; 3, moderate to severe.
Statistical Method
Values are means ± s.e.m., where n indicates number of animals. Statistical analyses were carried out on raw data using the Peritz F multiple means comparison test. Student's t-test was applied for unpaired data.
RESULTS
A 2B AR Mediates VEGF Production in Rat Glomeruli
Using isolated glomeruli from rat kidney we determined the role of A 2B AR on VEGF production ex vivo. The treatment of glomeruli with the general agonist of ARs induces an increase in the content of VEGF, which is in line with the previously determined increase in mRNA levels. 27 This increase was blocked by MRS1754, the selective antagonist of the A 2B and it was not observed when glomeruli were infected with an adenoviral vector expressing a short RNA that interferes with the expression of this AR subtype (Figure 1a) . No significant changes in the glomerular content of VEGF have been observed with pharmacological modulators of other ARs. 27 We determined that A 2B AR-mediated VEGF production required p42/44 MAPK and PKC signaling molecules activation (Figure 1a) . Particularly, we determined that p42/44 MAPK and PKCa isoform were phosphorylated upon A 2B AR activation (Figures 1b and c) . Released VEGF was also increased when the general AR agonist NECA was used. This effect was blocked by MRS1754 the selective antagonist of A 2B AR (Figure 2a) . In contrast, the selective agonist of A 1 AR decreased the basal release of VEGF from glomeruli. This effect could be blocked by using DPCPX, the selective antagonist of A 1 AR (Figure 2b ). 
Experimental Diabetes Increases the Expression of A 2B AR and VEGF in Kidney Glomeruli
The distribution of A 2B AR was assessed in rats' kidney by immunohistochemistry. The expression pattern of A 2B AR resembles that of VEGF in the glomeruli of healthy rats ( Figure 3 ). As early as 3 weeks following diabetes induction, we detected a stronger immunosignal and a wide distribution of A 2B AR in glomerular cells. Similarly, VEGF content was notably increased (Figure 3) . In contrast, the expression of the adenosine A 1 receptor subtype appears to decrease in diabetic rats glomeruli (Figure 3 ).
Glomerular Adenosine Availability
Owing to the fact that the A 2B AR exhibits a low affinity for the ligand, 23 changes in the extracellular adenosine availability should occur to mediate the physiologic effects. We quantified the extracellular concentration of adenine nucleotides and adenosine in glomeruli isolated from healthy and STZ-induced diabetic rats. Following 3 weeks of diabetes induction the contents of ATP, ADP and AMP were not different to the levels seen in normal rats glomeruli (Figure 4a ). However, a notably increase in the extracellular levels of adenosine were quantified in glomeruli of STZ-induced diabetic rats (Figure 4a) .
Furthermore, there was a correlation between the altered glomerular adenosine handling and the urinary excretion of the nucleoside. The mean adenosine urinary excretion rate was increased more than twofold in diabetic rats (Figure 4b ). 
Blockage of Diabetes-Induced VEGF Overproduction in MRS1754-Treated Rats
The exposure of ex vivo glomeruli to high glucose concentration induced an overproduction of VEGF (Figure 5a ). This result was specific to high glucose levels as using mannitol as osmotic control did not alter the content of VEGF (Figure 5b ). We observed that this high glucose effect was blocked when using the A 2B AR antagonist, by knocking down the receptor expression or using the PKC and ERK activation inhibitors (Figure 5a) .
In vivo analysis of the A 2B AR role on VEGF production were carried out in STZ-induced diabetic rats treated with the selective antagonist MRS1754. Following 4 weeks of diabetes induction, the administration of MRS1754 for 14 days blocked the glomerular increase in the expression of Figure 1) , and the increase in the urinary excretion of proteins induced by diabetes was blocked by the treatment using MRS1754 (Figure 6e) . Furthermore, the glomerular expression of aSMA, a mesangial cells myofibroblast transdifferentiation marker, was also blocked in the kidney of diabetic rats under the treatment with the A 2B AR antagonist (Figures 6a and d) . The blockade of VEGF induction and mesangial cells activation was in an early stage of glomerular dysfunction as only a decrease in the podocytes number was quantified while mesangial expansion has not yet occurred. A significant difference was detected in the patterns of glomerular WT-1 in all diabetic groups compared with healthy rats (Figures 6a  and f) . The treatment with MRS1754 did not modify the decreased glomerular WT-1 imnunosignals in diabetic rats. PAS staining was not changed by diabetes or treatment with the antagonist of A 2B AR in our experimental conditions (Figures 6a and g ).
The treatment with the A 2B AR antagonist did not alter the increased levels of plasma glucose in the STZ-induced diabetic rats. However, partial recovery of body weight was observed in rats following treatment with the antagonist (Table 1 ).
DISCUSSION
We demonstrate that the activity of A 2B AR has a pathogenic effect in the early glomerular dysfunctions observed in STZinduced diabetic rats and it can be blocked by using a selective antagonist in vivo. These alterations mediated by A 2B AR correlate with an increased expression of this receptor in rats' diabetic glomerulus. Furthermore, the pathogenic state also involves a decrease in the content of A 1 AR subtype in glomerular cells. This event, first described by Pawelczyk et al, 30 probably turns off the inhibitory effects on glomerular VEGF release accompanied with an increased production of this growth factor, as a consequence of the modulation of ARs activities by differential expression in the diabetic state. We also correlate the activity of a low-affinity AR with an increase in the ligand availability in glomeruli of diabetic rats. Interestingly, it was found elevated adenosine levels in plasma of clinically manifest DN patients compared with the basal levels of diabetic patients without DN and in healthy individuals. 31 Probably, the measurement of adenosine levels in plasma or urine could represent a novel specific marker to evaluate the progression of DN.
Recently, the pathogenic role of adenosine in mediating renal dysfunction and fibrosis in the adenosine desaminase knockout (ADA À / À ) mice model, with increased levels of the nucleoside, was described. 32 In addition, the progression of renal fibrosis generated in the ADA À / À animals or in mice infused with angiotensin II (Ang II)or subjected to unilateral ureteral obstruction can be blocked using an A 2B AR antagonist, suggesting a common pathogenic pathway involving adenosine signaling in chronic kidney disease. 32 Our major contribution is to demonstrate that this pathogenic pathway also occurs early in the progression of the renal disease derived from diabetes thus supporting the option of a DN pharmacological A 2B AR target intervention.
The pathomechanisms of DN converge in inducing a host of growth factors in the kidney. The fibrogenic cytokine transforming growth factor-beta 1 (TGF-b), through its Smad3 signaling pathway, is the etiologic agent of renal hypertrophy and the accumulation of mesangial extracellular matrix components and tubule-interstitial fibrosis in diabetes. However, there is limited evidence to support a role for TGF-b in the development of albuminuria. Podocyte-derived VEGF is a permeability and angiogenic factor whose expression is also increased in diabetic kidney diseases animal models. It appears to act in an autocrine signaling mode to induce the podocytopathy of diabetes, especially the genesis of proteinuria. 33 Therefore, currently strategies for DN therapy may need to involve interception of both the TGFb and the VEGF signaling pathways. In this way, the A 2B AR antagonist could be a valuable tool because it was demonstrated that it is able to block the increased release of TGF-b from diabetic glomeruli in vitro 22 and the myofibroblast transdifferentiation of masangial cells in vivo, as reported in this work. Similarly, interception of VEGF induction was a remarkable feature.
Studies have shown that the VEGF expression in renal podocytes increased upon exposure to high glucose concentration and it is intracellularly mediated by PKC-alpha and ERK1/2 signaling molecules. 34, 35 In addition, cultured podocytes exposed to high glucose concentration exhibit increased levels of extracellular adenosine. 36 Previously, we showed that the VEGF production increase in ex vivo glomeruli exposed to high glucose concentration could be blocked by MRS1754. 27 In consequence, our study in vivo suggests that A 2B AR could be a transducer of hyperglycemic conditions to mediate VEGF increase. Up to date, Ang II has been recognized as the major factor to increase VEGF expression in diabetic glomerular podocytes. 37 Intra-renal renin and angiotensinogen levels are induced in diabetic animals, 38, 39 and high glucose has been shown to stimulate renin and Ang II synthesis in mesangial cells and podocytes. 37, 40, 41 Further, the role of notch I signaling have also been recently associated with pathogenic VEGF induction and podocytopathy. 42 It remains to be determined if the use of A 2B AR antagonist could also intercept the activation of the renin-angiotensin system or notch I signaling.
The extracellular adenosine availability was shown to increase in diabetic glomeruli as shown by the higher urinary nucleoside levels. This effect could be linked to a decreased activity of ENT1 measured in isolated diabetic glomeruli. 22 Similar to our finding, ENT1 activity was found to be decreased in human endothelial cells isolated from gestational diabetes pregnancy 43 or in cells exposed to high glucose concentrations. 44, 45 This decreased activity of ENT1 elicits adenosine signaling by ARs as previously described, using inhibitors of ENT1 activity or in ENT1 À / À mice. 10, 19, 20 Interestingly, a correlation between ENT1 decreased activity with epithelium mesenchymal transition (EMT) of renal proximal tubule epithelial cells in vitro, was recently demonstrated. 46 EMT is a requisite for progression of tubule-interstitial fibrosis in the diabetic kidney disease. Indicate difference vs non-diabetic control rats (Po0.01).
b Indicate significant differences of treated rats vs diabetic rats (Po0.01).
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